<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Sept. 17, 2018 (HealthDay News) — For commonly prescribed cardiovascular drugs, there is no evidence that drug prices are influenced by their value, according to a study published in the August issue of Health Affairs<\/i>.<\/p>\n
Jonathan D. Campbell, Ph.D., from the University of Colorado in Aurora, and colleagues estimated the range of cost-effectiveness of 30 frequently prescribed cardiovascular drugs to examine whether drug prices are influenced by value. Evidence from randomized controlled trials was extrapolated to determine average lifetime quality-adjusted life-years (QALYs) and payer-related costs and to calculate the incremental cost-effectiveness ratios (ICERs).<\/p>\n
The researchers found that the ICERs varied from cost-saving with increased QALYs to more costly with decreased QALYs across the 30 drugs, suggesting that value does not consistently influence drug pricing.<\/p>\n
“Our study contributes to the growing body of evidence that can help inform payers in making more rational and systematic decisions and innovators in determinations of price,” the authors write.<\/p>\n
Several authors disclosed financial ties to Amgen, which partially funded the study.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n